Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity—a comparison of therapeutic effects and potential side effects with GCG-like peptide-1 inhibitors

Table 3 Summary of the hypoglycemic and weight loss effects of mazdutide at different doses

Ref.	Dose (mg)	HbA1c reduction (%)	Weight loss (%)	Achieving HbA1c < 7.0%	Adverse effects
Zhang et al[36], 2024	3	-1.41	-7.1	54%	Diarrhea (36%), nausea (23%)
	4.5	-1.35	-5.3	67%	Decreased appetite (29%)
	6	-1.67	-7.1	73%	Vomiting (14%), hypoglycemia (10%)
Ji et al[62], 2022	6, 9	N/A	6 mg: -6.1; 9 mg: -11.7	N/A	Nausea (23%), diarrhea (36%) (6 mg); nausea (28%), diarrhea (32%) (9 mg)
Ji et al[63], 2023	3, 4, 6	N/A	3 mg: -6.7; 4 mg: -10.4; 6 mg: -11.3	N/A	Diarrhea (36%), nausea (29%), vomiting (14%) (3 mg); diarrhea (38%), nausea (31%), vomiting (16%) (4 mg); diarrhea (36%), nausea (29%), vomiting (14%) (6 mg)
Ji et al[42], 2025	4, 6	N/A	4 mg: 11.0; 6 mg: -14.01	N/A	Nausea (25%), diarrhea (22%), transient tachycardia (4 mg); nausea (28%), diarrhea (25%), transient tachycardia (6 mg)
Dong et al[64], 2025	3	N/A	-14.8	N/A	Mild GI (vomiting, nausea)

N/A: Not applicable; HbA1c: Glycated hemoglobin A1c; GI: Gastrointestinal.